13th Workshop on Recent Issues in
Meet with Q2 Solutions at the 13th WRIB, booth 53, and learn how our bioanalytical and ADME laboratory solutions can instill confidence in your regulatory filings
About This EventJoin Q2 Solutions at the 13th WRIB, where over 900 professionals representing pharmaceutical/biopharmaceutical companies, CROs and multiple regulatory agencies convene to discuss current topics of interest in bioanalysis, biomarkers, and immunogenicity.
Plan to join Barry Jones, Q² Solutions’ Associate Director, LCMS Biologics and Biomarkers, for his podium presentation – details TBA.
We look forward to meeting you in New Orleans.
- Bioanalytical Laboratory Service
- Precision Medicine
- Central Laboratories
- Biomarker Services
- Innovative Laboratory Solutions
- Disruptive Technologies
Associate Director, LCMS Biologics and Biomarkers
Dr. Barry Jones joined Advion Biosciences in 2007 and began the LCMS Biologics Group in 2008. Barry now leads the large molecule LC-MS method development group at Q2 Solutions. Research within the LC-MS biologics group at Q2 Solutions is focused on targeted quantitative LC-MS/MS analysis of endogenous biomolecules and large molecule biotherapeutics on triple quadrupole and orbitrap instruments. Dr. Jones is particularly interested in the application of hybrid Immunoaffinity-LC-MS/MS methods to high-throughput bioanalysis, as well as the scientific challenges and regulatory strategies for validation of LC-MS biomarker assays supporting drug development in a regulated environment.
Prior to joining Q2 Solutions, Dr. Jones led the Mass Spectrometry Facility at Binghamton University, N.Y. using Q-TOF and MALDI mass spectrometry and nanoESI techniques in support of proteomic research. He earned his Ph.D. in Physical Chemistry at Binghamton University in 2006.
Updated as of September 2018.